Bulletin
Investor Alert

New York Markets Open in:

Annovis Bio Inc.

NYS: ANVS

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Jan 27, 2022, 7:14 a.m.

/zigman2/quotes/216213707/composite

$

14.27

Change

0.00 0.00%

Volume

Volume 200

Quotes are delayed by 20 min

/zigman2/quotes/216213707/composite

Previous close

$ 14.27

$ 14.27

Change

+0.25 +1.78%

Day low

Day high

$13.94

$15.50

Open

52 week low

52 week high

$9.71

$132.00

Open

Michael B. Hoffman

Founder of Northern Genesis Acquisition Corp., Northern Genesis Acquisition Corp. II, Northern Genesis Acquisition Corp. III and Stone Capital Partners LLC, Michael B. Hoffman is an entrepreneur and businessperson who has been at the head of 5 different companies and currently holds the position of Chairman of Annovis Bio, Inc., President for Northern Genesis Acquisition Corp. II, President for Northern Genesis Acquisition Corp. III and President of Northern Genesis Acquisition Corp. Michael B. Hoffman is also Member-Executive Council at International Institute For Nanotechnology, Partner at Stone Capital Partners LLC and Managing Director at Northern Genesis Climate Solutions Corp. and on the board of 14 other companies.

In the past Michael B. Hoffman occupied the position of Chairman at Onconova Therapeutics, Inc., Partner at Riverstone Holdings LLC and Partner at Riverstone Investment Group LLC (a subsidiary of Riverstone Holdings LLC), Senior Managing Director at The Blackstone Group, Inc. (Illinois), Managing Director & Co-Head-Mergers & Acquisitions at Smith Barney Harris Upham & Co., Inc. and Head-Mergers & Acquisitions at Smith Barney & Co., Inc.

He received a graduate degree and an undergraduate degree from Northwestern University and an MBA from Harvard Business School.

Transactions

Date Shares Transaction Value
01/04/2022 90   Derivative/Non-derivative trans. at $19.78 per share. 1,781
01/04/2022 7,142   Derivative/Non-derivative trans. at $0.25 per share. 1,785
01/04/2022 6,658   Derivative/Non-derivative trans. at $19.78 per share. 131,696
01/04/2022 30,000   Derivative/Non-derivative trans. at $4.39 per share. 131,700
01/31/2020 55,884   Derivative/Non-derivative trans. at $4.8 per share. 268,243
01/31/2020 1,137,942   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 158,730   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 33,333   Acquisition at $6 per share. 199,998

Officers and Executives

Dr. Maria-Luisa Maccecchini
President, Chief Executive Officer & Director
Mr. Jeffrey B. McGroarty
Chief Financial Officer
Ms. Cheng Fang
Vice President-Research
Mr. Michael B. Hoffman
Chairman
Mr. Reid S. McCarthy
Independent Director
Dr. Claudine E. Bruck
Independent Director
Mr. Mark White
Independent Director
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.